Ranibizumab differs from bevacizumab in terms of structure in that ranibizumab is a:

• A Full-length humanised monoclonal IgG1 antibody
• B VEGF-trap fusion protein binding VEGF-A and PlGF
• C Recombinant humanised antibody Fab fragment without the Fc region ✓
• D Pegylated aptamer targeting VEGF165

Explanation

Ranibizumab (Lucentis) is a recombinant humanised antibody Fab fragment designed specifically for intraocular use; lacking the Fc region reduces systemic absorption and complement activation. Bevacizumab (Avastin) is a full-length IgG1 antibody used off-label. Aflibercept (Eylea) is the VEGF-trap fusion protein binding VEGF-A, VEGF-B, and PlGF. Pegaptanib (Macugen) was the pegylated aptamer targeting only VEGF165.

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.